-
公开(公告)号:US20220380464A1
公开(公告)日:2022-12-01
申请号:US17739923
申请日:2022-05-09
Applicant: GENMAB A/S
Inventor: Rik RADEMAKER , Isil ALTINTAS , Patrick ENGELBERTS , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
公开(公告)号:US20210230296A1
公开(公告)日:2021-07-29
申请号:US17228023
申请日:2021-04-12
Applicant: GENMAB A/S
Inventor: David SATIJN , Esther C. W. BREIJ , Bart E. C. G. DE GOEIJ , Kristel KEMPER , Patrick ENGELBERTS , Edward N. VAN DEN BRINK , Rik RADEMAKER , Dennis VERZIJL , Sjeng HORBACH , Paul PARREN
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20200277397A1
公开(公告)日:2020-09-03
申请号:US16813167
申请日:2020-03-09
Applicant: GENMAB A/S
Inventor: David SATIJN , Esther C. W. BREIJ , Bart E. C. G. DE GOEIJ , Kristel KEMPER , Patrick ENGELBERTS , Edward N. VAN DEN BRINK , Rik RADEMAKER , Dennis VERZIJL , Sjeng HORBACH , Paul PARREN
Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
4.
公开(公告)号:US20230365714A1
公开(公告)日:2023-11-16
申请号:US18029472
申请日:2021-10-01
Applicant: GENMAB A/S
Inventor: Louise Koopman , Patrick ENGELBERTS , David SATIJN , Jan Hermen DANNENBERG
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/31 , C07K2317/565 , C07K2317/24 , C07K2317/35 , C07K2317/92
Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20230257479A1
公开(公告)日:2023-08-17
申请号:US17642488
申请日:2020-09-11
Applicant: GENMAB A/S
Inventor: David SATIJN , Esther C.W. BREIJ , Bart E.C.G. DE GOEIJ , Kristel KEMPER , Patrick ENGELBERTS , Edward N. VAN DEN BRINK , Rik RADEMAKER , Dennis VERZIJL , Sjeng HORBACH , Paul PARREN , Reshma Abdulla RANGWALA , Sri GHATTA , Ruud BRAKENHOFF , Rieneke VAN DE VEN
CPC classification number: C07K16/30 , A61P1/00 , A61P35/00 , A61K2039/505
Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
-
公开(公告)号:US20220324980A1
公开(公告)日:2022-10-13
申请号:US17695550
申请日:2022-03-15
Applicant: GENMAB A/S
Inventor: Louise KOOPMAN , Patrick ENGELBERTS , Dennis VERZIJL , Edward N. VAN DEN BRINK , Rik RADEMAKER , Sieto BOSGRA , Frederikke L. EGEROD , David SATIJN , Esther C. W BREIJ
Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20210292418A1
公开(公告)日:2021-09-23
申请号:US17204604
申请日:2021-03-17
Applicant: GENMAB A/S
Inventor: Louise KOOPMAN , Patrick ENGELBERTS , Dennis VERZIJL , Edward N. VAN DEN BRINK , Rik RADEMAKER , Sieto BOSGRA , Frederikke L. EGEROD , David SATIJN , Esther C. W. BREIJ
Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20190284278A1
公开(公告)日:2019-09-19
申请号:US15744317
申请日:2016-07-14
Applicant: GENMAB A/S
Inventor: Rik RADEMAKER , Isil ALTINTAS , Patrick ENGELBERTS , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
-
公开(公告)号:US20170355767A1
公开(公告)日:2017-12-14
申请号:US15541594
申请日:2016-01-08
Applicant: GENMAB A/S
Inventor: Patrick ENGELBERTS , Esther BREIJ , Rik RADEMAKER , Isil ALTINTAS , David SATIJN , Sandra VERPLOEGEN , Riemke VAN DIJKHUIZEN RADERSMA , Edward VAN DEN BRINK , Janine SCHUURMAN , Paul PARREN
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2809 , A61K39/39558 , A61K2039/505 , C07K16/2887 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/75 , C07K2317/90 , C07K2317/92 , C07K2317/94
Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
-
公开(公告)号:US20240228641A9
公开(公告)日:2024-07-11
申请号:US18478711
申请日:2023-09-29
Applicant: GENMAB A/S
Inventor: David SATIJN , Patrick ENGELBERTS , Kristel KEMPER , Esther C. W. BREIJ , Simone OOSTINDIE , Farshid ALEMDEHY
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2809 , C12N15/63 , C07K2317/31 , C07K2317/526 , C07K2317/565
Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
-
-
-
-
-
-
-
-
-